Integrated analyses uncover new features of atypical memory B cells and novel targets for intervention by Fuli Fan, Shubei Liu, Bin Wang, Xiaojian Song, Wei Wang

“…Alternation of AMB in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren's syndrome (SjS) was evaluated via bioinformatic approaches. …”
Get full text

Connective tissue disease-associated interstitial lung disease – A multicenter observational study from India by Sham Santhanam, Pravin Patil, Mohit Goyal, C B Mithun, Parthajit Das, Kavitha Mohanasundaram, Neeraj Jain, Vijaya Prasanna, Keerthi Talari, Himanshu Pathak, Parshant Aggarwal, Deepika Ponnuru, Vikram Raj Jain, Sharath Kumar

“…Results: A total of 620 patients (505 women) were recruited. Rheumatoid arthritis (RA) was the most common CTD associated with ILD followed by systemic sclerosis and mixed connective tissue disorder. …”
Get full text

Serological Immunoglobulin-Free Light Chain Profile in Myasthenia Gravis Patients by Umberto Basile, Mariapaola Marino, Cecilia Napodano, Krizia Pocino, Paolo Emilio Alboini, Francesca Gulli, Amelia Evoli, Carlo Provenzano, Emanuela Bartoccioni

“…Serological levels of free immunoglobulin light chains (FLCs), produced in excess of heavy chains during synthesis of immunoglobulins by plasma cells, can be considered a direct marker of B cell activity in different systemic inflammatory-autoimmune conditions and may represent a useful predictor of rituximab (RTX) therapeutic efficacy, as reported for rheumatoid arthritis and systemic lupus erythematosus. Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction with antibodies (abs) targeting the acetylcholine receptor (AChR) or the muscle-specific tyrosine kinase (MuSK), inducing muscle weakness and excessive fatigability. …”
Get full text

Cellular therapies in rheumatic and musculoskeletal diseases by Pedro Franco-Fuquen, Juana Figueroa-Aguirre, David A. Martínez, Eider F. Moreno-Cortes, Juan E. Garcia-Robledo, Fabio Vargas-Cely, Daniela A. Castro-Martínez, Mustafa Almaini, Januario E. Castro

“…These diseases, which include autoimmune disorders such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus, are marked by the presence of autoreactive B cells that play a critical role in their pathogenesis. …”
Get full text

بررسی ارتباط کیفیت خواب و درک درد در بیماران مبتلا به آرتریت روماتوئید by مهدی رضازاده, محمد امینی, فاطمه توفان, زهرا یوسفی

“…مقاله پژوهشیمقدمه: آرتریت روماتوئید (Rheumatoid Arthritis) RA، یک بیماری التهابی مزمن اتوایمیون است. …”
Get full text

The Patient-Reported Outcomes Thermometer–5-Item Scale (5T-PROs): Validation of a New Tool for the Quick Assessment of Overall Health Status in Painful Rheumatic Diseases by Fausto Salaffi, Marco Di Carlo, Marina Carotti, Sonia Farah

“…To investigate the construct validity, reliability (internal consistency and retest reliability), and feasibility of the patient-reported outcomes thermometer–5-item scale (5T-PROs), a new tool to measure overall health status in patients with painful chronic rheumatic diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axialSpA), and fibromyalgia (FM). …”
Get full text

Biomedical and candidate SN P markers of chronopathologies can significantly change affinity of ТАТА -binding protein for human gene promoters by D. A. Rasskazov, N. L. Podkolodnyy, O. A. Podkolodnaya, N. N. Podkolodnaya, V. V. Suslov, L. K. Savinkova, P. M. Ponomarenko, M. P. Ponomarenko

“…In the [–70; –20] region of promoters of 14 human genes (location of proven binding sites of ТВР), we found 32 known and candidate SNP markers of circadian- rhythm disturbances, including rs17231520 and rs569033466 (both: risk of chronopathologies in liver); rs35036378 (behavioral chronoaberrations); rs549858786 (rheumatoid arthritis with a chronoaberration of IL1B expression); rs563207167, rs11557611, and rs5505 (all three: chronopathologies of the tumor – host balance, blood pressure, and the reproductive system); rs1143627 (bipolar disorder with circadian dependence of diagnosis and treatment); rs16887226 and rs544850971 (both: lowered resistance to endotoxins because of the imbalance between the circadian and immune systems); rs367732974 and rs549591993 (both: circadian dependence of heart attacks); rs563763767 (circadian dependence of myocardial infarction); rs2276109 and rs572527200 (both: circadian dependence of asthma attacks); rs34223104, rs563558831, and rs10168 (circadian optima of treatment with methotrexate and cyclophosphamide); and rs397509430, rs33980857,rs34598529, rs33931746, rs33981098, rs34500389, rs63750953, rs281864525, rs35518301, and rs34166473 (all: neurosensory hearing loss and restless legs syndrome). …”
Get full text

Assessment of Physicochemical Properties of Rituximab Related to Its Immunomodulatory Activity by Mariana P. Miranda-Hernández, Carlos A. López-Morales, Nancy D. Ramírez-Ibáñez, Nelly Piña-Lara, Nestor O. Pérez, Aarón Molina-Pérez, Jorge Revilla-Beltri, Luis F. Flores-Ortiz, Emilio Medina-Rivero

“…Rituximab is a chimeric monoclonal antibody employed for the treatment of CD20-positive B-cell non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis. …”
Get full text

Porphyromonas gingivalis associates with the presence of anti-citrullinated protein antibodies, but not with the onset of arthritis: studies in an at-risk population by Helga Westerlind, Linda Mathsson-Alm, Alexandra Circiumaru, Aase Hensvold, Karin Lundberg, Jan Potempa, Yogan Kisten, Charlotte De Vries, Marina Dehara, Barbara Potempa

“…Objective The antibody response against Porphyromonas gingivalis (Pg) is elevated in rheumatoid arthritis (RA), especially in patients with anti-citrullinated protein antibodies (ACPA). …”
Get full text

Impact of COVID-19 on rheumatic diseases in india: Determinants of mortality and adverse outcome: A retrospective, cross-sectional cohort study by Avinash Jain, Vineeta Shobha, S Chandrashekara, Padmanabha Shenoy, Sapan C Pandya, Prakash Chotalia, Sharath Kumar, Sourabh Malviya, Yogesh Preet Singh, Abhishek Patil, Vikas Gupta, Puja Srivastava, Vijaya Prasanna Parimi, Chanakya Kodishala, Ramya Janardana, Benzeeta Pinto, Sudhir Bhandari, Govind Rankawat, Praveen Pratap Jadhav, Damodaram Potugari, Vishnu Sharma, Alpana Parmar, Sunitha Kayidhi, Paul T Antony, Ashish Badika, Amit Sharma

“…The mean age was 47.9 ± 14.4 years, including two children and 93 (20.8%) geriatric age group patients, male: female ratio was 0.4:1 and mean disease duration was 79.3 ± 77.1 months. Rheumatoid arthritis was the most common RD. Underlying disease was quiescent in 54.7% and active in 18.4% patients. …”
Get full text

Mendelian randomization analysis does not support a causal influence between lipoprotein(A) and immune-mediated inflammatory diseases by Yun Ti, Dan Xu, Xiaoning Qin, Yang Hu, Yuru Xu, Qingzhao Zhao, Peili Bu, Jingyuan Li

“…We performed a bidirectional two-sample mendelian randomization analyses based on genome-wide association study (GWAS) summary statistics of Lp(a) and nine IMIDs, specifically celiac disease (CeD), Crohn’s disease (CD), ulcerative colitis (UC), inflammatory bowel disease (IBD), multiple sclerosis (MS), psoriasis (Pso), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type 1 diabetes (T1D), and summary-level data for lipid traits. …”
Get full text

Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet’s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protoc... by Sander W Tas, Joost Raaphorst, Paco M J Welsing, Jacob M van Laar, Rogier M Thurlings, Robbert J Goekoop, César Magro Checa, Jan A M van Laar, Bettina C Geertsema-Hoeve, Nicolle H Rekers, Erik Present

“…The Drug Rediscovery in IMIDs (DRIMID) consortium aims to conduct a prospective pilot basket trial to investigate the effects of filgotinib, a JAK1 preferential inhibitor approved for ulcerative colitis and rheumatoid arthritis, on disease activity, quality of life and safety in patients with refractory BD, IIM and IgG4-RD.Methods and analysis In this investigator-initiated, multicentre, open-label phase 2 study, up to 60 patients with rare IMIDs will be enrolled for a 26-week treatment period with filgotinib 200 mg once daily. …”
Get full text

Anti-inflammatory treatment using alpha melanocyte stimulating hormone (α-MSH) does not alter osteoblasts differentiation and fracture healing by Johanna Graue, Melanie Timmen, Katharina Schmitz, Daniel Kronenberg, Markus Böhm, Kishor K. Sivaraj, M. Gabriele Bixel, Richard Stange

“…Abstract Background Alpha-melanocyte-stimulating-hormone (α-MSH) has been identified as a new anti-inflammatory treatment compound in rheumatoid arthritis (RA) and other inflammatory diseases. …”
Get full text

PADI4 Haplotypes in Association with RA Mexican Patients, a New Prospect for Antigen Modulation by Maria Guadalupe Zavala-Cerna, Norma Guadalupe Gonzalez-Montoya, Arnulfo Nava, Jorge I. Gamez-Nava, Maria Cristina Moran-Moguel, Roberto Carlos Rosales-Gomez, Susan Andrea Gutierrez-Rubio, Jose Sanchez-Corona, Laura Gonzalez-Lopez, Ingrid Patricia Davalos-Rodriguez, Mario Salazar-Paramo

“…Four SNPs (single nucleotide polymorphisms) have been described in PADI4 gene to form a susceptibility haplotype for rheumatoid arthritis (RA); nevertheless, results in association studies appear contradictory in different populations. …”
Get full text

Can screening for degenerative cervical myelopathy (SCREEN-DCM) be effectively undertaken based on signs, symptoms and known risk factors? Rationale and research protocol for a pro... by Benjamin Davies, Mark Kotter, Granit Molliqaj, Enrico Tessitore, Karl Schaller, Teresa Somma, Aria Nouri, Renato Gondar, Joseph S Cheng, Paolo Cappabianca, Alexandre Lavé, Gianpaolo Jannelli, Allan Martin, Justin Virojanapa, Carmen L A Vleggeert-Lankamp, Valerie ter Wengel, Torstein Meling

“…Points are attributed based on the presence of signs/symptoms of DCM (eg, Hoffmann sign, hyper-reflexia) and for comorbidities that predispose or are frequently associated with cervical myelopathy (eg, rheumatoid arthritis, carpal tunnel syndrome). Patients with ≥3 points undergo cervical MRI examination. …”
Get full text

Anti-TROVE2 Antibody Determined by Immune-Related Array May Serve as a Predictive Marker for Adalimumab Immunogenicity and Effectiveness in RA by Po-Ku Chen, Joung-Liang Lan, Yi-Ming Chen, Hsin-Hua Chen, Shih-Hsin Chang, Chia-Min Chung, Nurul H. Rutt, Ti-Myen Tan, Raja Nurashirin Raja Mamat, Nur Diana Anuar, Jonathan M. Blackburn, Der-Yuan Chen

“…Anti-drug antibody (ADAb) development is associated with secondary therapeutic failure in biologic-treated rheumatoid arthritis (RA) patients. With a treat-to-target goal, we aimed to identify biomarkers for predicting ADAb development and therapeutic response in adalimumab-treated patients. …”
Get full text

The current state of knowledge on the role of NKG2D ligands in multiple sclerosis and other autoimmune diseases by Aleksandra Pogoda-Wesołowska, Nina Sługocka, Agnieszka Synowiec, Klaudia Brodaczewska, Marcin Mejer-Zahorowski, Maciej Ziękiewicz, Wojciech Szypowski, Piotr Szymański, Adam Stępień

“…In this review, we aim to describe the role of NKG2D and NKG2DLs, and their interactions in the pathogenesis of MS, as well as in other autoimmune diseases such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), and celiac disease (CeD). …”
Get full text

Search for signals of positive selection of circadian rhythm genes <i>PER1</i>, <i>PER2</i>, <i>PER3</i> in different human populations by A. I. Mishina, S. Y. Bakoev, A. Y. Oorzhak, A. A. Keskinov, Sh. Sh. Kabieva, A. V. Korobeinikova, V. S. Yudin, M. M. Bobrova, D. A. Shestakov, V. V. Makarov, L. V. Getmantseva

“…In addition, many of the selection variants in the PER1, PER2, PER3 genes appear to regulate biological processes that are associated with major modern diseases, including obesity, cancer, metabolic syndrome, bipolar personality disorder, depression, rheumatoid arthritis, diabetes mellitus, lupus erythematosus, stroke and Alzheimer’s disease, making them extremely interesting targets for further research aimed at identifying the genetic causes of human disease.…”
Get full text

Systemic Resolvin E1 (RvE1) Treatment Does Not Ameliorate the Severity of Collagen-Induced Arthritis (CIA) in Mice: A Randomized, Prospective, and Controlled Proof of Concept Study by Rafael Scaf de Molon, Rogier M. Thurlings, Birgitte Walgreen, Monique M. Helsen, Peter M. van der Kraan, Joni Augusto Cirelli, Marije I. Koenders

“…Thus, this study is aimed at determining whether systemic RvE1 treatment reduces arthritis onset and severity in murine collagen-induced arthritis (CIA) and spontaneous cytokine production by human rheumatoid arthritis (RA) synovial explants. 10-week-old DBA1/J male mice were subjected to CIA and treated systemically with 0.1 μg RvE1, 1 μg RvE1, 5 mg/kg anti-TNF (positive control group), PBS (negative control group), or with a combination of 1 μg of RvE1 plus 5 mg/kg anti-TNF using prophylactic or therapeutic strategies. …”
Get full text

Identification of novel autoantibodies in Sjögren’s disease by Fiona Engelke, Petra Budde, Salvatore De Vita, Thomas Dörner, Diana Ernst, Jan Gras, Harald Heidecke, Annika Loredana Kilian, Katja Kniesch, Ann-Sophie Lindemann, Luca Quartuccio, Jacob Ritter, Kai Schulze-Forster, Benjamin Seeliger, Hans-Dieter Zucht, Torsten Witte

“…To assess disease specificity, the novel autoantibodies were also measured in serum of patients with Rheumatoid Arthritis (RA, n=50), Systemic Lupus Erythematosus (SLE, n=49), and Systemic Sclerosis (SSc, n=37). …”
Get full text